Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011951 | 0.96 | STAT3 (0.47) | STAT3STAT1DCTPP1GCGRDHFR | |
| SCHEMBL3527775 | 0.80 | STAT3 (0.43) | STAT3STAT1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL4551743 | 0.79 | STAT3 (0.44) | STAT3STAT1KDM4EHSD17B10 | |
| SCHEMBL7262704 | 0.78 | STAT3 (0.50) | STAT3STAT1GCGRDHFR | |
| SCHEMBL17419215 | 0.78 | STAT3 (0.43) | STAT3STAT1KDM4EHSD17B10 | |
| SCHEMBL27971649 | 0.77 | STAT3 (0.44) | STAT3STAT1DCTPP1GCGRDHFR | |
| SCHEMBL5133634 | 0.77 | STAT3 (0.42) | STAT3STAT1KDM4EHSD17B10 | |
| SCHEMBL28252316 | 0.76 | STAT3 (0.45) | STAT3STAT1DCTPP1GCGRDHFR | |
| SCHEMBL6003904 | 0.76 | STAT3 (0.41) | STAT3STAT1KDM4EHSD17B10 | |
| SCHEMBL15510967 | 0.76 | STAT3 (0.41) | STAT3STAT1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417142-B2 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
| US-6951935-B2 | Heteroatom-substituted porphyrins and methods for synthesis of same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-06-09 | — | — | US | disclosed |
| US-20030236400-A1 | Heteroatom-substituted porphyrins and methods for synthesis of same | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | STAT3 3817/4885STAT1 4312/4885DCTPP1 3738/4885 |
| US-20030236400-A1 | Heteroatom-substituted porphyrins and methods for synthesis of same | PPOX, HMBS, UROD | STAT3 4156/4885STAT1 3973/4885DCTPP1 709/4885 |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | PPOX, PPIF, HMBS | STAT3 2986/4885STAT1 3579/4885DCTPP1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.